Aardvark Therapeutics has received Institutional Review Board (IRB) approval in the US for an amended protocol to its Phase III HERO clinical trial of ARD-101 underway for hyperphagia in Prader-Willi ...
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results